September 18, 2014Thrombosis and Haemostasis
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?
Why the study?
Does tailored antiplatelet therapy based on platelet function testing improve clinical outcomes in patients treated with P2Y12 receptor inhibitors?
Population
Patients treated with P2Y12 receptor inhibitors, including those with ST-elevation myocardial infarction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Does not support routine platelet function testing to guide antiplatelet therapy in low-to-moderate risk patients; leaves open utility in higher-risk settings.
Structured PICO
Does tailored antiplatelet therapy based on platelet function testing improve clinical outcomes in patients treated with P2Y12 receptor inhibitors?
P
Population
Patients treated with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor), including those with ST-elevation myocardial infarction
I
Intervention
Tailored antiplatelet therapy based on platelet function testing, pharmacogenomic testing, and clinical scoring
Recent clinical trials do not support the routine use of platelet function testing to tailor antiplatelet therapy in low-to-moderate risk patients.
Cite This Study
Trenk et al. (2014) studied this question.